Laboratoire Francais du Fractionnement et des Biotechnologies S.A.
BiotechLaboratoire Francais du Fractionnement et des Biotechnologies S.A. is a biotechnology company with 1 FDA-approved products.
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.'s Key Drugs
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.'s core commercial portfolio centers on Sevenfact — its most strategically important drugs approved in the last 15 years.
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.'s Recent FDA Approvals
New NDA/BLA approvals for Laboratoire Francais du Fractionnement et des Biotechnologies S.A. over the last two years — novel drugs only, excluding generics and label supplements.
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.'s Therapeutic Areas
Disease areas where Laboratoire Francais du Fractionnement et des Biotechnologies S.A. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Laboratoire Francais du Fractionnement et des Biotechnologies S.A. Pipeline Snapshot
Active clinical trials for Laboratoire Francais du Fractionnement et des Biotechnologies S.A. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Sevenfact leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-03-31
- Latest
- 2020-03-31
- Applications
- 1